(lp0
S"Alzheimer's Cure Is Science's Holy Grail - Will Biogen Find It? Seeking Alpha - Mar 27, 2017 Biogen's main business for now is multiple sclerosis. But sales could be hurt soon by a new drug from Roche. In the last months, there have been two failures in Alzheimer's disease trials from Eli Lilly and Merck."
p1
aS"Biogen Inc: MS drug patent ruling win clears uncertainty Times of India - Mar 21, 2017 U.S. patent office says key patent on Biogen's top-seller and market-leading oral multiple sclerosis  treatment, Tecfidera, protect drug until at least 2026 and beyond."
p2
aS"Biogen Inc.  Pulled Back Sharply After Downgrade RTT News - Mar 17, 2017 Morgan Stanley downgraded its rating on shares of Biogen Inc.  Thursday morning to &quot;Equal weight&quot; from &quot;Overweight.Why Guess?, Inc. , Biogen Inc  and Snap Inc  Are 3 of Today's ... - Investorplace.comMorgan Stanley Takes A Breather On Biogen, Downgrades Stock - Benzinga"
p3
aS"Revenue Approximations Analysis: Biogen Inc. , The Wendy's Company  StockNewsJournal - Mar 27, 2017 Investors who are keeping close eye on the stock of Biogen Inc.  established that the company was able to keep return on investment at 20.31 in the trailing twelve month while Reuters data showed that industry's average stands at 13.48 and&nbsp;..."
p4
aS"Better Buy: Biogen Inc. vs. Gilead Sciences Inc. Motley Fool - Feb 27, 2017 The two stocks do already compete in a sense, though, for investors' affections. That's a battle where Biogen has come out on top over the last year."
p5
aS"Institutional Ownership Update on Biogen Inc.  Midway Monitor - 17 hours ago Biogen Inc. 's stock has been a favorite of smart money aka institutions, as of late. Institutions are currently holders of 89.40% of the shares.The Biogen Inc  PT Set at $296.00 by Credit Suisse Group AG - Petro Global News 24Biogen Inc  Stock Rating Upgraded by Vetr Inc. - Chaffey Breeze"
p6
aS"Biogen wins patent ruling for its $4 billion MS treatment The Boston Globe - Mar 21, 2017 Shares of Biogen Inc. were trading up 1.5 percent early Tuesday afternoon after the Cambridge biotech's patent on its top-selling multiple sclerosis treatment was upheld by a legal ruling.Court Victory Benefits Biogen And Its Tecfidera Rival Alike - Seeking AlphaBiogen prevails in dispute over key Tecfidera patent - Boston Business Journal"
p7
aS"Taking a Look at the Chart for Biogen Inc.  The USA Commerce - 13 hours ago We have gathered the technical data on Biogen Inc. , and see some interesting trends in the stock's behavior of late."
p8
aS'Analyst Observation On 2 Stocks: Biogen Inc. , Vulcan Materials Company ... Post Analyst - 15 hours ago Biogen Inc. has a consensus outperform rating from 27 Wall Street analysts, and the number of shares currently sold short amount to at least 1.26% of shares outstanding.'
p9
aS"Taking a Fresh Look at Biogen Inc.  StockNewsJournal - Mar 22, 2017 Biogen Inc.  is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $275.79, up from yesterday's close by 0.36%.81184 Shares in Biogen Inc  Acquired by Assenagon Asset Management SA - BNB Daily Camber Capital Management LLC Invests $49626000 in Biogen Inc  - The Cerbat Gem"
p10
a.